---
document_datetime: 2023-09-21 19:34:36
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps/altargo-epar-procedural-steps-taken-authorisation_en.pdf
document_name: altargo-epar-procedural-steps-taken-authorisation_en.pdf
version: success
processing_time: 0.4046634
conversion_datetime: 2025-12-19 03:28:24.999124
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
## BACKGROUND INFORMATION ON THE PROCEDURE

## 1. Submission of the dossier

The  applicant Glaxo  Group  Ltd.  submitted on 14 June 2006  an application for  Marketing Authorisation  to  the  European  Medicines  Agency  (EMEA)  for  Altargo,  through  the  centralised procedure  under  Article  3  (2)  (a)  of  Regulation  (EC)  No  726/2004. The  eligibility  to  the  Central Procedure was agreed upon by the EMEA/CHMP on 1 June 2006.

•

•

- The CHMP opinions were forwarded, in all official languages of the European Union, to the European Commission, which adopted the corresponding Decisions on 24 May 2007.

The legal basis for this application refers to: Article 8.3 of Directive 2001/83/EC, as amended - complete and independent application Scientific Advice: The applicant received Scientific Advice from the CHMP on 23 April 2004. The Scientific Advice pertained to non-clinical and clinical aspects of the dossier. Licensing status: A new application was filed in the following country: USA The product was not licensed in any country at the time of submission of this application. The Rapporteur and Co-Rapporteur appointed by the CHMP were: Rapporteur: Frances Rotblat Co-Rapporteur: Karl Broich 2. Steps taken for the assessment of the product · The application was received by the EMEA on 14 June 2006. · The procedure started on 19 July 2006 · The Rapporteur's first Assessment Report was circulated to all  CHMP  members  on 18 September 2006. The Co-Rapporteur's first Assessment Report was circulated to all CHMP members on 29 September 2006. · During the meeting on 13-16 November 2006, the CHMP agreed on the consolidated List of Questions to be sent to the applicant. The final consolidated List of Questions was sent to the applicant on 16 November 2006. · The  applicant  submitted  the  responses  to  the  CHMP  consolidated  List  of  Questions  on 14 December 2006. · The Rapporteurs circulated the Joint Assessment Report on the applicant's responses to the List of Questions to all CHMP members on 25 January 2007. · During the CHMP meeting on 19-22 February 2007, the CHMP agreed on a list of outstanding issues to be addressed in writing by the applicant. The applicant submitted the responses to the CHMP list of outstanding issues on 5 March 2007. During the meeting on 19-22 March 2007 the CHMP, in the light of the overall data submitted and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for  granting  a Marketing  Authorisation  to  Altargo  on  22  March  2007 . The  applicant  provided  the  letter  of undertaking on the follow-up measures to be fulfilled post-authorisation on 20 March 2007 Medicinal product no longer authorised